Singapore Clamps Down on Foreign Interference Involving South Asians 
The Dark Side of Asia’s ‘Miracle Diet’ 
Thailand Seeks to Revive Its Peninsular White Elephant 
By: Tomoaki Takei
Multinational pharma giant Eli Lilly’s Mounjaro (tirzepatide), the dual GIP/GLP-1 receptor agonist, is at the center of a rapidly escalating public health storm in East Asia. While clinically approved as a life-saving treatment for Type 2 diabetes, the drug has been effectively deified on social media as the ultimate cosmetic weight-los…
Don't Miss:
-
Singapore Clamps Down on Foreign Interference Involving South Asians
-
Thailand Seeks to Revive Its Peninsular White Elephant
-
John Geyman Advocate for Single Payer National Health Insurance
-
Malaysia’s Anwar Faces A Reformist Archrival
-
Trump intelligence adviser previously helped father pursue millions from Kremlin-linked bank, leaked documents show